*School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;

†Faculty of Medicine, Leiden University Medical Centre, Leiden University, Leiden, the Netherlands;

‡Neurology Department, Westmead Hospital, Westmead, Australia;

§Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; and

¶Westmead Hospital, Westmead, New South Wales, Australia.

Correspondence: Hannah Yejin Kim, PhD, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, A15 Science Rd, Camperdown, NSW 2006, Australia (e-mail: [email protected]).

Y. Goo wrote and structured the manuscript. A. M. der Nederlanden contributed as the second reviewer to the results, and H. Y. Kim participated in the quality assessment. A. Bleasel provided expertise on the research findings and latest treatment guidelines related to antiepileptic drug use in pregnant women with epilepsy. J.-W. Alffenaar and H. Y. Kim offered proficiency in TDM research methodologies and findings, and guided the authors with review topic organization, research question formulation, and manuscript writing. All authors contributed to manuscript refinement.

The authors declare no conflict of interest.

No ethical approvals were required for this systematic review.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.drug-monitoring.com).